Thioredoxin 1 Suppresses TXNIP-Driven Control of Glucose Metabolism in Human Cells
Antioxidants & Redox Signaling · 01.05.2026 · 44 (13-15) · 643-660
DOI: 10.1177/15230864261421616 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antioxidants & Redox Signaling, online erschienen am 24.02.2026. Verfasst von Shayida Maimaiti und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Biochemistry and Biophysics, Division of Biochemistry, Karolinska Institutet, Stockholm, Sweden. Hauptthemen laut MEDLINE: Thioredoxins, Glucose, Carrier Proteins. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 83 Literaturangaben.
Abstract (Originalsprache)
Aims
Cytosolic thioredoxin 1 (Trx1, TXN, TRX) is a central player in redox control. Thioredoxin interacting protein (TXNIP), an α-arrestin regulating glucose metabolism and inflammation, is widely regarded to inhibit TRX activity. However, the interactions between the two proteins across various cellular contexts remain poorly understood; in addition, only a limited number of studies have yet been conducted in human primary cells. We thus aimed here to investigate the functional relationship between TRX and TXNIP in human primary cells. We studied whether TXNIP inhibits TRX cellular activity in these primary cells and how this interaction influences cellular redox biology or glucose metabolism.
Results
In primary cells, TXNIP deficiency did not increase cellular TRX activity. Instead, TXNIP deficiency elevated PGC-1α and PDK4 transcripts, increased PDHA1 Ser293 phosphorylation, and raised basal GLUT4, consistent with enhanced glucose uptake and restrained flux through the pyruvate dehydrogenase complex. Conversely, lowering TRX expression levels triggered higher TXNIP levels. This in turn correlated with suppressed transcripts for PGC-1α and PDK4, a lower extent of PDHA1 phosphorylation at Ser293, and decreased glucose uptake. Innovation: Our findings suggest that TXNIP, against common belief, may not necessarily be an endogenous inhibitor of TRX but, rather, that TRX can be an inhibitor of TXNIP.
Conclusion
This study reveals that the key intracellular redox protein TRX inversely regulates TXNIP, suggesting that modulation of the TRX system may provide a previously unrecognized therapeutic avenue for modulation of glucose metabolism. Antioxid. Redox Signal. 44, 643–660.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Biochemistry and Biophysics, Division of Biochemistry, Karolinska Institutet, Stockholm, Sweden.
- Institute of Diagnostic Laboratory Medicine, Clinical Chemistry and Pathobiochemistry, Charité-Universitätsmedizin Berlin, Berlin, Germany.
- Max Rubner Center (MRC) for Cardiovascular Metabolic Renal Research, Charité-Universitätsmedizin Berlin, Berlin, Germany.
- Department of Selenoprotein Research, National Institute of Oncology, Budapest, Hungary.
Zitieren
APA
Maimaiti, S., Dagnell, M., Coppo, L., Zhao, W., Geserick, P., Kappert, K., & Arnér, E. S. J. (2026). Thioredoxin 1 Suppresses TXNIP-Driven Control of Glucose Metabolism in Human Cells. Antioxidants & Redox Signaling, 44(13-15), 643-660. https://doi.org/10.1177/15230864261421616
Vancouver
Maimaiti S, Dagnell M, Coppo L, Zhao W, Geserick P, Kappert K, et al. Thioredoxin 1 Suppresses TXNIP-Driven Control of Glucose Metabolism in Human Cells. Antioxidants & Redox Signaling. 2026;44(13-15):643-660. doi:10.1177/15230864261421616
BibTeX
@article{Maimaiti2026,
author = {Maimaiti, Shayida and Dagnell, Markus and Coppo, Lucia and Zhao, Wenchao and Geserick, Peter and Kappert, Kai and Arnér, Elias S J},
title = {Thioredoxin 1 Suppresses TXNIP-Driven Control of Glucose Metabolism in Human Cells},
journal = {Antioxidants & Redox Signaling},
year = {2026},
volume = {44},
number = {13-15},
pages = {643--660},
doi = {10.1177/15230864261421616}
}
EUVIMED